pharmaphorum

DECEMBER 23, 2022

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). And in 2023, these investments will hopefully pay off. They’ve laid the necessary groundwork for cross-functional visibility, collaboration, and connectivity.

Marketing 94

Marketing Sales Medical Patients 94

Clarivate

MARCH 8, 2023

In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. The Professional Society for Health Economics and Outcomes Research (ISPOR) has cited real world evidence (RWE) as the number one trend in healthcare decision making for the second year running [1].

Patients 59

Patients Biopharma Medical science Electronics 59

PM360

MARCH 22, 2024

Field Medical Affairs is an essential bridge between pharmaceutical clinical development and commercial delivery. Historically, the industry has left MSL-HCP interactions to exist on their own, focusing on objective metrics and key performance indicators (KPIs) to inform Medical Affairs impact. October 2023. EPG Health.

Medical 52

Medical Education Sales Medical science 52

Clarivate

JUNE 21, 2024

One recent review reported a 77% reduction in human screening time (Van Dijk, 2023), however authors did acknowledge that a substantial period of time was required for researchers to become familiar with using the AI tool in the first place. CRDs guidance for undertaking reviews in healthcare. Cochrane Crowd [Online]. Bucsan, C.

Training 81

Training Government Medical science Ethics 81

European Pharmaceutical Review

MAY 2, 2023

Expanding this approach to simultaneously build capabilities and clinical trials in developing and underserved regions, like APAC and less wealthy healthcare systems in Latin America and Europe, is essential to driving more comprehensive clinical programmes and health equity. cited 2023 Apr 4]. 2019 [cited 2023 Apr 4].

Patients 105

Patients Medicine Marketing Medical 105

Pharmaceutical Technology

NOVEMBER 3, 2022

The Australian Department of Health and Aged Care published a similar statement on August 25, stating that tenecteplase shortages will likely affect the country until the end of 2023. As a result, healthcare providers need to rely on generic manufacturers, but there are only a few who make them, he explains.

Medicine 111

Medicine Manufacturing Pharmacology Healthcare 111

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. This trial is anticipated to begin in the second half of 2023.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105